{"pmid":32452700,"title":"COVID-19: Safe Guidelines for Breast Imaging During the Pandemic.","text":["COVID-19: Safe Guidelines for Breast Imaging During the Pandemic.","During the COVID-19 pandemic, breast imaging must be performed using safe practices. Balancing the need to avoid delays in the diagnosis of breast cancer while avoiding infection requires careful attention to personal protective equipment and physical distancing and vigilance to maintain these practices. The Canadian Society of Breast Imaging/Canadian Association of Radiologists guideline for breast imaging during COVID-19 is provided based on priority according to risk of breast cancer and impact of delaying treatment. A review of the best practices is presented that allow breast imaging during COVID-19 to maximize protection of patients, technologists, residents, fellows, and radiologists and minimize spread of the infection. The collateral damage of delaying diagnosis of breast cancer due to COVID-19 should be avoided when possible.","Can Assoc Radiol J","Seely, Jean M","Scaranelo, Anabel M","Yong-Hing, Charlotte","Appavoo, Shusheila","Flegg, Carolyn","Kulkarni, Supriya","Kornecki, Anat","Wadden, Nancy","Loisel, Yves","Schofield, Stephanie","Leslie, Sandra","Gordon, Paula","32452700"],"abstract":["During the COVID-19 pandemic, breast imaging must be performed using safe practices. Balancing the need to avoid delays in the diagnosis of breast cancer while avoiding infection requires careful attention to personal protective equipment and physical distancing and vigilance to maintain these practices. The Canadian Society of Breast Imaging/Canadian Association of Radiologists guideline for breast imaging during COVID-19 is provided based on priority according to risk of breast cancer and impact of delaying treatment. A review of the best practices is presented that allow breast imaging during COVID-19 to maximize protection of patients, technologists, residents, fellows, and radiologists and minimize spread of the infection. The collateral damage of delaying diagnosis of breast cancer due to COVID-19 should be avoided when possible."],"journal":"Can Assoc Radiol J","authors":["Seely, Jean M","Scaranelo, Anabel M","Yong-Hing, Charlotte","Appavoo, Shusheila","Flegg, Carolyn","Kulkarni, Supriya","Kornecki, Anat","Wadden, Nancy","Loisel, Yves","Schofield, Stephanie","Leslie, Sandra","Gordon, Paula"],"date":"2020-05-27T11:00:00Z","year":2020,"_id":"32452700","source":"PubMed","week":"202022|May 25 - May 31","doi":"10.1177/0846537120928864","keywords":["covid-19","breast cancer","breast imaging","delayed diagnosis","guideline"],"topics":["Prevention"],"weight":1,"_version_":1667983494550126594,"score":9.490897,"similar":[{"pmid":32449757,"title":"Weathering the Storm: Managing Older Adults with Breast Cancer Amid COVID-19 and Beyond.","text":["Weathering the Storm: Managing Older Adults with Breast Cancer Amid COVID-19 and Beyond.","Caring for older patients with breast cancer presents unique clinical considerations due to preexisting and competing comorbidity, the potential for treatment-related toxicity, and the consequent impact on functional status. In the context of the COVID-19 pandemic, treatment decision-making for older patients is especially challenging and encourages us to re-focus our treatment priorities. While we work to avoid treatment delays and maintain therapeutic benefit, we also need to minimize the risk for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) exposures, myelosuppression, general chemotherapy toxicity, and functional decline. Herein, we propose multidisciplinary care considerations for the aging patient with breast cancer, with the goal to promote a team-based, multidisciplinary treatment approach during the COVID-19 pandemic and beyond. These considerations remain relevant as we navigate the 'new normal' for the approximately 30% of breast cancer patients age >/=70 years who are diagnosed in the U.S. annually and for the thousands of older patients living with recurrent and/or metastatic disease.","J Natl Cancer Inst","Freedman, Rachel A","Sedrak, Mina S","Bellon, Jennifer R","Block, Caroline C","Lin, Nancy U","King, Tari A","Minami, Christina","VanderWalde, Noam","Jolly, Trevor A","Muss, Hyman B","Winer, Eric P","32449757"],"abstract":["Caring for older patients with breast cancer presents unique clinical considerations due to preexisting and competing comorbidity, the potential for treatment-related toxicity, and the consequent impact on functional status. In the context of the COVID-19 pandemic, treatment decision-making for older patients is especially challenging and encourages us to re-focus our treatment priorities. While we work to avoid treatment delays and maintain therapeutic benefit, we also need to minimize the risk for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) exposures, myelosuppression, general chemotherapy toxicity, and functional decline. Herein, we propose multidisciplinary care considerations for the aging patient with breast cancer, with the goal to promote a team-based, multidisciplinary treatment approach during the COVID-19 pandemic and beyond. These considerations remain relevant as we navigate the 'new normal' for the approximately 30% of breast cancer patients age >/=70 years who are diagnosed in the U.S. annually and for the thousands of older patients living with recurrent and/or metastatic disease."],"journal":"J Natl Cancer Inst","authors":["Freedman, Rachel A","Sedrak, Mina S","Bellon, Jennifer R","Block, Caroline C","Lin, Nancy U","King, Tari A","Minami, Christina","VanderWalde, Noam","Jolly, Trevor A","Muss, Hyman B","Winer, Eric P"],"date":"2020-05-26T11:00:00Z","year":2020,"_id":"32449757","source":"PubMed","week":"202022|May 25 - May 31","doi":"10.1093/jnci/djaa079","keywords":["covid-19","breast cancer","elderly","older patients"],"locations":["USA"],"countries":["United States"],"countries_codes":["USA|United States"],"topics":["Prevention"],"weight":1,"_version_":1667785213919363073,"score":460.53418},{"pmid":32368252,"pmcid":"PMC7192402","title":"Neoadjuvant endocrine therapy for luminal breast cancer treatment: a first-choice alternative in times of crisis such as the COVID-19 pandemic.","text":["Neoadjuvant endocrine therapy for luminal breast cancer treatment: a first-choice alternative in times of crisis such as the COVID-19 pandemic.","The epidemiological emergency caused by CoV-2 (COVID-19) has changed priorities in breast cancer management. In those places where the pandemic has had the greatest effect, it is of paramount importance for most patients to be at home, reducing or postponing their attendance at clinics, as well as avoiding surgeries. In this scenario, neoadjuvant endocrine treatment could be an appropriate alternative treatment for hormone receptor positive breast cancer (luminal-like tumours) in order to minimise hospital admissions and to delay elective surgeries. Accordingly, we present a simple protocol that can be applied to most cases of luminal-like breast cancer and is appropriate for the majority of secondary or tertiary medical centres, or even primary care.","Ecancermedicalscience","Marti, Covadonga","Sanchez-Mendez, Jose I","32368252"],"abstract":["The epidemiological emergency caused by CoV-2 (COVID-19) has changed priorities in breast cancer management. In those places where the pandemic has had the greatest effect, it is of paramount importance for most patients to be at home, reducing or postponing their attendance at clinics, as well as avoiding surgeries. In this scenario, neoadjuvant endocrine treatment could be an appropriate alternative treatment for hormone receptor positive breast cancer (luminal-like tumours) in order to minimise hospital admissions and to delay elective surgeries. Accordingly, we present a simple protocol that can be applied to most cases of luminal-like breast cancer and is appropriate for the majority of secondary or tertiary medical centres, or even primary care."],"journal":"Ecancermedicalscience","authors":["Marti, Covadonga","Sanchez-Mendez, Jose I"],"date":"2020-05-06T11:00:00Z","year":2020,"_id":"32368252","source":"PubMed","week":"202019|May 04 - May 10","doi":"10.3332/ecancer.2020.1027","keywords":["covid-19","breast cancer","endocrine therapy","luminal","neoadjuvant"],"topics":["Prevention"],"weight":1,"_version_":1666138496290521088,"score":442.76987},{"pmid":32359937,"pmcid":"PMC7172676","title":"COVID-19 impact on timing of brachytherapy treatment and strategies for risk mitigation.","text":["COVID-19 impact on timing of brachytherapy treatment and strategies for risk mitigation.","PURPOSE: The purpose of this study was to highlight the importance of timely brachytherapy treatment for patients with gynecologic, breast, and prostate malignancies, and provide a framework for brachytherapy clinical practice and management in response to the COVID-19 pandemic. METHODS AND MATERIALS: We review amassing evidence to help guide the management and timing of brachytherapy for gynecologic, breast, and prostate cancers. Where concrete data could not be found, peer-reviewed expert opinion is provided. RESULTS: There may be a significant negative impact on oncologic outcomes for patients with gynecologic malignancies who have a delay in the timely completion of therapy. Delay of prostate or breast cancer treatment may also impact oncologic outcomes. If a treatment delay is expected, endocrine therapy may be an appropriate temporizing measure before delivery of radiation therapy. The use of shorter brachytherapy fractionation schedules will help minimize patient exposure and conserve resources. CONCLUSIONS: Brachytherapy remains a critical treatment for patients and may shorten treatment time and exposure for some. Reduced patient exposure and resource utilization is important during COVID-19. Every effort should be made to ensure timely brachytherapy delivery for patients with gynecologic malignancies, and endocrine therapy may help temporize treatment delays for breast and prostate cancer patients. Physicians should continue to follow developing institutional, state, and federal guidelines/recommendations as challenges in delivering care during COVID-19 will continue to evolve.","Brachytherapy","Williams, Vonetta M","Kahn, Jenna M","Harkenrider, Matthew M","Chino, Junzo","Chen, Jonathan","Fang, L Christine","Dunn, Emily F","Fields, Emma","Mayadev, Jyoti S","Rengan, Ramesh","Petereit, Daniel","Dyer, Brandon A","32359937"],"abstract":["PURPOSE: The purpose of this study was to highlight the importance of timely brachytherapy treatment for patients with gynecologic, breast, and prostate malignancies, and provide a framework for brachytherapy clinical practice and management in response to the COVID-19 pandemic. METHODS AND MATERIALS: We review amassing evidence to help guide the management and timing of brachytherapy for gynecologic, breast, and prostate cancers. Where concrete data could not be found, peer-reviewed expert opinion is provided. RESULTS: There may be a significant negative impact on oncologic outcomes for patients with gynecologic malignancies who have a delay in the timely completion of therapy. Delay of prostate or breast cancer treatment may also impact oncologic outcomes. If a treatment delay is expected, endocrine therapy may be an appropriate temporizing measure before delivery of radiation therapy. The use of shorter brachytherapy fractionation schedules will help minimize patient exposure and conserve resources. CONCLUSIONS: Brachytherapy remains a critical treatment for patients and may shorten treatment time and exposure for some. Reduced patient exposure and resource utilization is important during COVID-19. Every effort should be made to ensure timely brachytherapy delivery for patients with gynecologic malignancies, and endocrine therapy may help temporize treatment delays for breast and prostate cancer patients. Physicians should continue to follow developing institutional, state, and federal guidelines/recommendations as challenges in delivering care during COVID-19 will continue to evolve."],"journal":"Brachytherapy","authors":["Williams, Vonetta M","Kahn, Jenna M","Harkenrider, Matthew M","Chino, Junzo","Chen, Jonathan","Fang, L Christine","Dunn, Emily F","Fields, Emma","Mayadev, Jyoti S","Rengan, Ramesh","Petereit, Daniel","Dyer, Brandon A"],"date":"2020-05-04T11:00:00Z","year":2020,"_id":"32359937","source":"PubMed","week":"202019|May 04 - May 10","doi":"10.1016/j.brachy.2020.04.005","keywords":["brachytherapy","breast cancer","covid-19","covid19","cervical cancer","coronavirus","prostate cancer","radiation oncology","radiotherapy","uterine cancer"],"locations":["Physicians"],"topics":["Prevention"],"weight":1,"_version_":1666138495941345280,"score":412.27692},{"pmid":32503827,"title":"Breast Cancer Surgery During the COVID-19 Pandemic: An Observational Clinical Study of the Breast Surgery Clinic at Ospedale Policlinico San Martino - Genoa, Italy.","text":["Breast Cancer Surgery During the COVID-19 Pandemic: An Observational Clinical Study of the Breast Surgery Clinic at Ospedale Policlinico San Martino - Genoa, Italy.","BACKGROUND: COVID-19 pandemic required a marked re-allocation of healthcare resources, including at Breast Units. A patient-tailored program was developed to assess its efficacy regarding prevention of COVID-19 infection among patients with breast cancer undergoing surgery and healthcare workers (HCWs). PATIENTS AND METHODS: From March 9th to April 9th 2020, 91 patients were selected for elective surgery by means of: i) Pre-hospital screening aimed at avoiding hospitalization of symptomatic or suspicious COVID-19 patients, and ii) prioritisation of surgical procedure according to specific disease features. RESULTS: Eighty-five patients (93.4%) were fit for surgery, while five patients (5.5%) were temporarily excluded through 'telephone triage'; another two patients were excluded at in-hospital triage. A total of 71 out of 85 patients (83.5%) were diagnosed with invasive cancer, most of whom were undergoing breast-conserving surgery (61 out of 85 patients, 71.8%). The mean in-hospital stay was 2.2 days (SD=0.7 days). After hospital discharge, no patient needed re-admission due to post-operative complications; moreover, no COVID-19 infection among patients or HCWs was detected. CONCLUSION: Safe breast cancer surgery was accomplished for both patients and HCWs by means of a careful preoperative selection of patients and in-hospital preventative measures. This screening program can be transferred to high-volume Breast Units and it may be useful in implementing European Community recommendations for prevention of COVID-19 infection.","In Vivo","Fregatti, Piero","Gipponi, Marco","Giacchino, Maria","Sparavigna, Marco","Murelli, Federica","Toni, Maria Luisa","Calabro, Maria Teresa","Orsino, Lina","Friedman, Daniele","32503827"],"abstract":["BACKGROUND: COVID-19 pandemic required a marked re-allocation of healthcare resources, including at Breast Units. A patient-tailored program was developed to assess its efficacy regarding prevention of COVID-19 infection among patients with breast cancer undergoing surgery and healthcare workers (HCWs). PATIENTS AND METHODS: From March 9th to April 9th 2020, 91 patients were selected for elective surgery by means of: i) Pre-hospital screening aimed at avoiding hospitalization of symptomatic or suspicious COVID-19 patients, and ii) prioritisation of surgical procedure according to specific disease features. RESULTS: Eighty-five patients (93.4%) were fit for surgery, while five patients (5.5%) were temporarily excluded through 'telephone triage'; another two patients were excluded at in-hospital triage. A total of 71 out of 85 patients (83.5%) were diagnosed with invasive cancer, most of whom were undergoing breast-conserving surgery (61 out of 85 patients, 71.8%). The mean in-hospital stay was 2.2 days (SD=0.7 days). After hospital discharge, no patient needed re-admission due to post-operative complications; moreover, no COVID-19 infection among patients or HCWs was detected. CONCLUSION: Safe breast cancer surgery was accomplished for both patients and HCWs by means of a careful preoperative selection of patients and in-hospital preventative measures. This screening program can be transferred to high-volume Breast Units and it may be useful in implementing European Community recommendations for prevention of COVID-19 infection."],"journal":"In Vivo","authors":["Fregatti, Piero","Gipponi, Marco","Giacchino, Maria","Sparavigna, Marco","Murelli, Federica","Toni, Maria Luisa","Calabro, Maria Teresa","Orsino, Lina","Friedman, Daniele"],"date":"2020-06-07T11:00:00Z","year":2020,"_id":"32503827","source":"PubMed","week":"202023|Jun 01 - Jun 07","doi":"10.21873/invivo.11959","keywords":["covid-19","breast cancer","clinical management"],"locations":["Italy"],"countries":["Italy"],"countries_codes":["ITA|Italy"],"topics":["Prevention"],"weight":1,"_version_":1668892488293679104,"score":411.88803},{"pmid":32412693,"title":"Personalized risk-benefit ratio adaptation of Breast Cancer care at the epicentre of Covid-19 outbreak.","text":["Personalized risk-benefit ratio adaptation of Breast Cancer care at the epicentre of Covid-19 outbreak.","Northern Italy has been one of the European regions reporting the highest number of Covid-19 cases and deaths. The pandemic spread has challenged the National Health System (NHS), requiring re-allocation of most of the available healthcare resources to treat Covid-19 positive patients, generating a competition with other healthcare needs, including cancer. Cancer patients are at higher risk of developing critical illness after Covid-19 infection. Thus, mitigation strategies should be adopted to reduce the likelihood of infection in all cancer patients. At the same time, suboptimal care and treatments may result in worse cancer-related outcome. In this paper, we attempt to estimate the individual risk-benefit balance to define personalized strategies for optimal breast cancer management, avoiding as much as possible a general untailored approach. We discuss and report the strategies our Breast Unit adopted from the beginning of the Covid-19 outbreak to ensure the continuum of the best possible cancer care for our patients while mitigating the risk of infection, despite limited healthcare resources.","Oncologist","Viale, Giulia","Licata, Luca","Sica, Lorenzo","Zambelli, Stefania","Zucchinelli, Patrizia","Rognone, Alessia","Aldrighetti, Daniela","Di Micco, Rosa","Zuber, Veronica","Pasetti, Marcella","Di Muzio, Nadia","Rodighiero, Maria Grazia","Panizza, Pietro","Sassi, Isabella","Petrella, Giovanna","Cascinu, Stefano","Gentilini, Oreste Davide","Bianchini, Giampaolo","32412693"],"abstract":["Northern Italy has been one of the European regions reporting the highest number of Covid-19 cases and deaths. The pandemic spread has challenged the National Health System (NHS), requiring re-allocation of most of the available healthcare resources to treat Covid-19 positive patients, generating a competition with other healthcare needs, including cancer. Cancer patients are at higher risk of developing critical illness after Covid-19 infection. Thus, mitigation strategies should be adopted to reduce the likelihood of infection in all cancer patients. At the same time, suboptimal care and treatments may result in worse cancer-related outcome. In this paper, we attempt to estimate the individual risk-benefit balance to define personalized strategies for optimal breast cancer management, avoiding as much as possible a general untailored approach. We discuss and report the strategies our Breast Unit adopted from the beginning of the Covid-19 outbreak to ensure the continuum of the best possible cancer care for our patients while mitigating the risk of infection, despite limited healthcare resources."],"journal":"Oncologist","authors":["Viale, Giulia","Licata, Luca","Sica, Lorenzo","Zambelli, Stefania","Zucchinelli, Patrizia","Rognone, Alessia","Aldrighetti, Daniela","Di Micco, Rosa","Zuber, Veronica","Pasetti, Marcella","Di Muzio, Nadia","Rodighiero, Maria Grazia","Panizza, Pietro","Sassi, Isabella","Petrella, Giovanna","Cascinu, Stefano","Gentilini, Oreste Davide","Bianchini, Giampaolo"],"date":"2020-05-16T11:00:00Z","year":2020,"_id":"32412693","source":"PubMed","week":"202020|May 11 - May 17","doi":"10.1634/theoncologist.2020-0316","keywords":["covid-19","sars-cov-2","breast cancer","treatment"],"topics":["Prevention"],"weight":1,"_version_":1666897318920585216,"score":398.80832}]}